Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Celcuity ( (CELC) ).
On September 9, 2025, Celcuity Inc. announced an amendment to its senior secured credit facility, increasing the total loan size to $500 million with Innovatus Capital Partners and Oxford Finance. This amendment enhances Celcuity’s financial flexibility, supporting its FDA submission for gedatolisib and other strategic initiatives, following positive data from a Phase 3 clinical study.
The most recent analyst rating on (CELC) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Celcuity stock, see the CELC Stock Forecast page.
Spark’s Take on CELC Stock
According to Spark, TipRanks’ AI Analyst, CELC is a Neutral.
Celcuity’s stock score of 43.73 reflects the challenges faced by early-stage biotech firms. The company’s financial performance is weak due to lack of revenue and high expenses. Technical analysis shows a neutral to slightly negative outlook, while valuation metrics are poor due to negative earnings. Despite these challenges, the earnings call provided a positive outlook with potential future revenue and strong financial positioning. The overall score indicates significant risks but potential for future growth if clinical and financial milestones are achieved.
To see Spark’s full report on CELC stock, click here.
More about Celcuity
Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for oncology. Its lead therapeutic candidate is gedatolisib, a potent inhibitor targeting the PI3K/AKT/mTOR pathway, with ongoing clinical trials for various solid tumor indications. The company is headquartered in Minneapolis.
Average Trading Volume: 1,240,666
Technical Sentiment Signal: Buy
Current Market Cap: $2.65B
Find detailed analytics on CELC stock on TipRanks’ Stock Analysis page.